{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:32:50Z","timestamp":1774974770164,"version":"3.50.1"},"reference-count":186,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,3,9]],"date-time":"2014-03-09T00:00:00Z","timestamp":1394323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s40266-014-0160-x","type":"journal-article","created":{"date-parts":[[2014,3,8]],"date-time":"2014-03-08T10:17:40Z","timestamp":1394273860000},"page":"239-261","source":"Crossref","is-referenced-by-count":28,"title":["Challenges and Promises in the Development of Neurotrophic Factor-Based Therapies for Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"31","author":[{"given":"Tiago Martins","family":"Rodrigues","sequence":"first","affiliation":[]},{"given":"Andr\u00e9","family":"Jer\u00f3nimo-Santos","sequence":"additional","affiliation":[]},{"given":"Tiago Fleming","family":"Outeiro","sequence":"additional","affiliation":[]},{"given":"Ana Maria","family":"Sebasti\u00e3o","sequence":"additional","affiliation":[]},{"given":"Maria Jos\u00e9","family":"Di\u00f3genes","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2014,3,9]]},"reference":[{"issue":"6","key":"160_CR1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"LM Lau de","year":"2006","unstructured":"de Lau LM, Breteler MM. Epidemiology of Parkinson\u2019s disease. Lancet Neurol. 2006;5(6):525\u201335.","journal-title":"Lancet Neurol"},{"issue":"4","key":"160_CR2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic J. Parkinson\u2019s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368\u201376.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"160_CR3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","volume":"5","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson\u2019s disease: diagnosis and management. Lancet Neurol. 2006;5(3):235\u201345.","journal-title":"Lancet Neurol"},{"issue":"Suppl 17","key":"160_CR4","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.1002\/mds.21676","volume":"22","author":"T Gasser","year":"2007","unstructured":"Gasser T. Update on the genetics of Parkinson\u2019s disease. Mov Disord. 2007;22(Suppl 17):S343\u201350.","journal-title":"Mov Disord."},{"issue":"8","key":"160_CR5","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrneurol.2013.132","volume":"9","author":"J Trinh","year":"2013","unstructured":"Trinh J, Farrer M. Advances in the genetics of Parkinson disease. Nat Rev Neurol. 2013;9(8):445\u201354.","journal-title":"Nat Rev Neurol."},{"key":"160_CR6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-genom-082410-101440","volume":"12","author":"I Martin","year":"2011","unstructured":"Martin I, Dawson VL, Dawson TM. Recent advances in the genetics of Parkinson\u2019s disease. Annu Rev Genomics Hum Genet. 2011;12:301\u201325.","journal-title":"Annu Rev Genomics Hum Genet."},{"issue":"4","key":"160_CR7","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00005072-199804000-00005","volume":"57","author":"MC Irizarry","year":"1998","unstructured":"Irizarry MC, Growdon W, Gomez-Isla T, Newell K, George JM, Clayton DF, et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson\u2019s disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol. 1998;57(4):334\u20137.","journal-title":"J Neuropathol Exp Neurol."},{"issue":"6645","key":"160_CR8","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839\u201340.","journal-title":"Nature."},{"issue":"3","key":"160_CR9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.bbrc.2006.10.085","volume":"351","author":"TF Outeiro","year":"2006","unstructured":"Outeiro TF, Klucken J, Strathearn KE, Liu F, Nguyen P, Rochet JC, et al. Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. Biochem Biophys Res Commun. 2006;351(3):631\u20138.","journal-title":"Biochem Biophys Res Commun."},{"issue":"32","key":"160_CR10","doi-asserted-by":"crossref","first-page":"10209","DOI":"10.1021\/bi020139h","volume":"41","author":"TT Ding","year":"2002","unstructured":"Ding TT, Lee SJ, Rochet JC, Lansbury PT Jr. Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry. 2002;41(32):10209\u201317.","journal-title":"Biochemistry."},{"issue":"4","key":"160_CR11","doi-asserted-by":"crossref","first-page":"e1867","DOI":"10.1371\/journal.pone.0001867","volume":"3","author":"TF Outeiro","year":"2008","unstructured":"Outeiro TF, Putcha P, Tetzlaff JE, Spoelgen R, Koker M, Carvalho F, et al. Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One. 2008;3(4):e1867.","journal-title":"PLoS One."},{"issue":"12","key":"160_CR12","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1096\/fj.05-5422com","volume":"20","author":"J Klucken","year":"2006","unstructured":"Klucken J, Outeiro TF, Nguyen P, McLean PJ, Hyman BT. Detection of novel intracellular alpha-synuclein oligomeric species by fluorescence lifetime imaging. FASEB J. 2006;20(12):2050\u20137.","journal-title":"FASEB J."},{"issue":"5556","key":"160_CR13","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1126\/science.1067389","volume":"295","author":"PK Auluck","year":"2002","unstructured":"Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson\u2019s disease. Science. 2002;295(5556):865\u20138.","journal-title":"Science."},{"issue":"1","key":"160_CR14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.0.CO;2-E","volume":"58","author":"DF Clayton","year":"1999","unstructured":"Clayton DF, George JM. Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res. 1999;58(1):120\u20139.","journal-title":"J Neurosci Res."},{"issue":"2","key":"160_CR15","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ncb748","volume":"4","author":"H Fujiwara","year":"2002","unstructured":"Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, et al. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4(2):160\u20134.","journal-title":"Nat Cell Biol."},{"issue":"10","key":"160_CR16","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1021\/bi991447r","volume":"39","author":"KA Conway","year":"2000","unstructured":"Conway KA, Harper JD, Lansbury PT Jr. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson\u2019s disease are typical amyloid. Biochemistry. 2000;39(10):2552\u201363.","journal-title":"Biochemistry."},{"issue":"5","key":"160_CR17","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0022-2836(02)00735-0","volume":"322","author":"HA Lashuel","year":"2002","unstructured":"Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, et al. Alpha-synuclein, especially the Parkinson\u2019s disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol. 2002;322(5):1089\u2013102.","journal-title":"J Mol Biol."},{"issue":"14","key":"160_CR18","doi-asserted-by":"crossref","first-page":"10737","DOI":"10.1074\/jbc.M010907200","volume":"276","author":"VN Uversky","year":"2001","unstructured":"Uversky VN, Li J, Fink AL. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem. 2001;276(14):10737\u201344.","journal-title":"J Biol Chem."},{"key":"160_CR19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.biochem.74.082803.133400","volume":"74","author":"MR Cookson","year":"2005","unstructured":"Cookson MR. The biochemistry of Parkinson\u2019s disease. Annu Rev Biochem. 2005;74:29\u201352.","journal-title":"Annu Rev Biochem."},{"issue":"13","key":"160_CR20","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1096\/fj.03-0098fje","volume":"17","author":"OM El-Agnaf","year":"2003","unstructured":"El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, Gibson MJ, et al. Alpha-synuclein implicated in Parkinson\u2019s disease is present in extracellular biological fluids, including human plasma. Faseb J. 2003;17(13):1945\u20137.","journal-title":"Faseb J."},{"issue":"5","key":"160_CR21","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0955-0674(02)00377-0","volume":"14","author":"PT Lansbury Jr","year":"2002","unstructured":"Lansbury PT Jr, Brice A. Genetics of Parkinson\u2019s disease and biochemical studies of implicated gene products. Curr Opin Cell Biol. 2002;14(5):653\u201360.","journal-title":"Curr Opin Cell Biol."},{"issue":"5837","key":"160_CR22","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1126\/science.1143780","volume":"317","author":"TF Outeiro","year":"2007","unstructured":"Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson\u2019s disease. Science. 2007;317(5837):516\u20139.","journal-title":"Science."},{"key":"160_CR23","doi-asserted-by":"crossref","unstructured":"Diogenes MJ, Dias RB, Rombo DM, Vicente Miranda H, Maiolino F, Guerreiro P, et al. Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci. 2012;32(34):11750\u201362.","DOI":"10.1523\/JNEUROSCI.0234-12.2012"},{"issue":"5","key":"160_CR24","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/dneu.20768","volume":"70","author":"KK Teng","year":"2010","unstructured":"Teng KK, Felice S, Kim T, Hempstead BL. Understanding proneurotrophin actions: recent advances and challenges. Dev Neurobiol. 2010;70(5):350\u20139.","journal-title":"Dev Neurobiol."},{"issue":"6314","key":"160_CR25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/350158a0","volume":"350","author":"DR Kaplan","year":"1991","unstructured":"Kaplan DR, Martin-Zanca D, Parada LF. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature. 1991;350(6314):158\u201360.","journal-title":"Nature."},{"issue":"1","key":"160_CR26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0092-8674(91)90419-Y","volume":"65","author":"R Klein","year":"1991","unstructured":"Klein R, Jing SQ, Nanduri V, O\u2019Rourke E, Barbacid M. The trk proto-oncogene encodes a receptor for nerve growth factor. Cell. 1991;65(1):189\u201397.","journal-title":"Cell."},{"issue":"5","key":"160_CR27","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/0896-6273(91)90287-A","volume":"7","author":"LR Berkemeier","year":"1991","unstructured":"Berkemeier LR, Winslow JW, Kaplan DR, Nikolics K, Goeddel DV, Rosenthal A. Neurotrophin-5: a novel neurotrophic factor that activates trk and trkB. Neuron. 1991;7(5):857\u201366.","journal-title":"Neuron."},{"issue":"5","key":"160_CR28","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/0092-8674(91)90395-F","volume":"65","author":"SP Squinto","year":"1991","unstructured":"Squinto SP, Stitt TN, Aldrich TH, Davis S, Bianco SM, Radziejewski C, et al. trkB encodes a functional receptor for brain-derived neurotrophic factor and neurotrophin-3 but not nerve growth factor. Cell. 1991;65(5):885\u201393.","journal-title":"Cell."},{"issue":"5","key":"160_CR29","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/0092-8674(91)90442-2","volume":"66","author":"F Lamballe","year":"1991","unstructured":"Lamballe F, Klein R, Barbacid M. trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell. 1991;66(5):967\u201379.","journal-title":"Cell."},{"issue":"13","key":"160_CR30","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00018-006-6010-1","volume":"63","author":"JC Arevalo","year":"2006","unstructured":"Arevalo JC, Wu SH. Neurotrophin signaling: many exciting surprises! Cell Mol Life Sci. 2006;63(13):1523\u201337.","journal-title":"Cell Mol Life Sci."},{"issue":"3","key":"160_CR31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0955-2235(89)90008-2","volume":"1","author":"T Ebendal","year":"1989","unstructured":"Ebendal T. NGF in CNS: experimental data and clinical implications. Prog Growth Factor Res. 1989;1(3):143\u201359.","journal-title":"Prog Growth Factor Res."},{"issue":"4","key":"160_CR32","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1152\/physrev.1980.60.4.1284","volume":"60","author":"H Thoenen","year":"1980","unstructured":"Thoenen H, Barde YA. Physiology of nerve growth factor. Physiol Rev. 1980;60(4):1284\u2013335.","journal-title":"Physiol Rev."},{"issue":"3","key":"160_CR33","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1073\/pnas.88.3.961","volume":"88","author":"B Knusel","year":"1991","unstructured":"Knusel B, Winslow JW, Rosenthal A, Burton LE, Seid DP, Nikolics K, et al. Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin 3. Proc Natl Acad Sci U\u00a0S\u00a0A. 1991;88(3):961\u20135.","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"2","key":"160_CR34","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1523\/JNEUROSCI.10-02-00558.1990","volume":"10","author":"B Knusel","year":"1990","unstructured":"Knusel B, Michel PP, Schwaber JS, Hefti F. Selective and nonselective stimulation of central cholinergic and dopaminergic development in vitro by nerve growth factor, basic fibroblast growth factor, epidermal growth factor, insulin and the insulin-like growth factors I and II. J Neurosci. 1990;10(2):558\u201370.","journal-title":"J Neurosci."},{"issue":"2","key":"160_CR35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1460-9568.1995.tb01058.x","volume":"7","author":"L Studer","year":"1995","unstructured":"Studer L, Spenger C, Seiler RW, Altar CA, Lindsay RM, Hyman C. Comparison of the effects of the neurotrophins on the morphological structure of dopaminergic neurons in cultures of rat substantia nigra. Eur J Neurosci. 1995;7(2):223\u201333.","journal-title":"Eur J Neurosci."},{"issue":"6315","key":"160_CR36","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/350230a0","volume":"350","author":"C Hyman","year":"1991","unstructured":"Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP, et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature. 1991;350(6315):230\u20132.","journal-title":"Nature."},{"issue":"10","key":"160_CR37","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/BF00966824","volume":"17","author":"E Garcia","year":"1992","unstructured":"Garcia E, Rios C, Sotelo J. Ventricular injection of nerve growth factor increases dopamine content in the striata of MPTP-treated mice. Neurochem Res. 1992;17(10):979\u201382.","journal-title":"Neurochem Res."},{"issue":"1\u20132","key":"160_CR38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/0006-8993(95)01513-2","volume":"713","author":"PB Kirschner","year":"1996","unstructured":"Kirschner PB, Jenkins BG, Schulz JB, Finkelstein SP, Matthews RT, Rosen BR, et al. NGF, BDNF and NT-5, but not NT-3 protect against MPP+ toxicity and oxidative stress in neonatal animals. Brain Res. 1996;713(1\u20132):178\u201385.","journal-title":"Brain Res."},{"issue":"1\u20132","key":"160_CR39","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.neulet.2005.12.042","volume":"398","author":"RK Chaturvedi","year":"2006","unstructured":"Chaturvedi RK, Shukla S, Seth K, Agrawal AK. Nerve growth factor increases survival of dopaminergic graft, rescue nigral dopaminergic neurons and restores functional deficits in rat model of Parkinson\u2019s disease. Neurosci Lett. 2006;398(1\u20132):44\u20139.","journal-title":"Neurosci Lett."},{"key":"160_CR40","doi-asserted-by":"crossref","unstructured":"Salinas M, Diaz R, Abraham NG, Ruiz de Galarreta CM, Cuadrado A. Nerve growth factor protects against 6-hydroxydopamine-induced oxidative stress by increasing expression of heme oxygenase-1 in a phosphatidylinositol 3-kinase-dependent manner. J Biol Chem. 2003;278(16):13898\u2013904.","DOI":"10.1074\/jbc.M209164200"},{"issue":"1","key":"160_CR41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0304-3940(99)00463-2","volume":"270","author":"M Mogi","year":"1999","unstructured":"Mogi M, Togari A, Kondo T, Mizuno Y, Komure O, Kuno S, et al. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson\u2019s disease. Neurosci Lett. 1999;270(1):45\u20138.","journal-title":"Neurosci Lett."},{"key":"160_CR42","doi-asserted-by":"crossref","unstructured":"Lorigados Pedre L, Pavon Fuentes N, Alvarez Gonzalez L, McRae A, Serrano Sanchez T, Blanco Lescano L, et al. Nerve growth factor levels in Parkinson disease and experimental parkinsonian rats. Brain Res. 2002;952(1):122\u20137.","DOI":"10.1016\/S0006-8993(02)03222-5"},{"issue":"2","key":"160_CR43","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1006\/exnr.1996.0034","volume":"137","author":"I Date","year":"1996","unstructured":"Date I, Ohmoto T. Neural transplantation and trophic factors in Parkinson\u2019s disease: special reference to chromaffin cell grafting, NGF support from pretransected peripheral nerve, and encapsulated dopamine-secreting cell grafting. Exp Neurol. 1996;137(2):333\u201344.","journal-title":"Exp Neurol."},{"issue":"3","key":"160_CR44","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/cne.903420302","volume":"342","author":"KB Seroogy","year":"1994","unstructured":"Seroogy KB, Lundgren KH, Tran TM, Guthrie KM, Isackson PJ, Gall CM. Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs. J Comp Neurol. 1994;342(3):321\u201334.","journal-title":"J Comp Neurol."},{"issue":"1","key":"160_CR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1369\/jhc.6A6952.2006","volume":"55","author":"HT Zhang","year":"2007","unstructured":"Zhang HT, Li LY, Zou XL, Song XB, Hu YL, Feng ZT, et al. Immunohistochemical distribution of NGF, BDNF, NT-3, and NT-4 in adult rhesus monkey brains. J Histochem Cytochem. 2007;55(1):1\u201319.","journal-title":"J Histochem Cytochem."},{"issue":"26","key":"160_CR46","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.1523\/JNEUROSCI.4601-04.2005","volume":"25","author":"ZC Baquet","year":"2005","unstructured":"Baquet ZC, Bickford PC, Jones KR. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J Neurosci. 2005;25(26):6251\u20139.","journal-title":"J Neurosci."},{"issue":"1","key":"160_CR47","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.expneurol.2010.12.018","volume":"228","author":"M Baydyuk","year":"2011","unstructured":"Baydyuk M, Nguyen MT, Xu B. Chronic deprivation of TrkB signaling leads to selective late-onset nigrostriatal dopaminergic degeneration. Exp Neurol. 2011;228(1):118\u201325.","journal-title":"Exp Neurol."},{"issue":"1","key":"160_CR48","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1523\/JNEUROSCI.14-01-00335.1994","volume":"14","author":"C Hyman","year":"1994","unstructured":"Hyman C, Juhasz M, Jackson C, Wright P, Ip NY, Lindsay RM. Overlapping and distinct actions of the neurotrophins BDNF, NT-3, and NT-4\/5 on cultured dopaminergic and GABAergic neurons of the ventral mesencephalon. J Neurosci. 1994;14(1):335\u201347.","journal-title":"J Neurosci."},{"issue":"1","key":"160_CR49","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1471-4159.1992.tb08880.x","volume":"59","author":"MB Spina","year":"1992","unstructured":"Spina MB, Squinto SP, Miller J, Lindsay RM, Hyman C. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J Neurochem. 1992;59(1):99\u2013106.","journal-title":"J Neurochem."},{"issue":"6","key":"160_CR50","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1073\/pnas.0913572107","volume":"107","author":"SW Jang","year":"2010","unstructured":"Jang SW, Liu X, Yepes M, Shepherd KR, Miller GW, Liu Y, et al. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc Natl Acad Sci U\u00a0S\u00a0A. 2010;107(6):2687\u201392.","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"12","key":"160_CR51","doi-asserted-by":"crossref","first-page":"7810","DOI":"10.1523\/JNEUROSCI.15-12-07810.1995","volume":"15","author":"M Levivier","year":"1995","unstructured":"Levivier M, Przedborski S, Bencsics C, Kang UJ. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson\u2019s disease. J Neurosci. 1995;15(12):7810\u201320.","journal-title":"J Neurosci."},{"key":"160_CR52","doi-asserted-by":"crossref","unstructured":"Tsukahara T, Takeda M, Shimohama S, Ohara O, Hashimoto N. Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. Neurosurgery. 1995;37(4):733\u20139; discussion 9\u201341.","DOI":"10.1227\/00006123-199510000-00018"},{"issue":"8","key":"160_CR53","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/00001756-199505300-00009","volume":"6","author":"CW Shults","year":"1995","unstructured":"Shults CW, Kimber T, Altar CA. BDNF attenuates the effects of intrastriatal injection of 6-hydroxydopamine. Neuroreport. 1995;6(8):1109\u201312.","journal-title":"Neuroreport."},{"issue":"11","key":"160_CR54","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1073\/pnas.91.11.5104","volume":"91","author":"DM Frim","year":"1994","unstructured":"Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci U\u00a0S\u00a0A. 1994;91(11):5104\u20138.","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"10","key":"160_CR55","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s11064-011-0491-5","volume":"36","author":"YX Ding","year":"2011","unstructured":"Ding YX, Xia Y, Jiao XY, Duan L, Yu J, Wang X, et al. The TrkB-positive dopaminergic neurons are less sensitive to MPTP insult in the substantia nigra of adult C57\/BL mice. Neurochem Res. 2011;36(10):1759\u201366.","journal-title":"Neurochem Res."},{"key":"160_CR56","doi-asserted-by":"crossref","unstructured":"von Bohlen und Halbach O, Minichiello L, Unsicker K. Haploinsufficiency for trkB and trkC receptors induces cell loss and accumulation of alpha-synuclein in the substantia nigra. FASEB J. 2005;19(12):1740\u20132.","DOI":"10.1096\/fj.05-3845fje"},{"issue":"2","key":"160_CR57","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0014-5793(92)81430-T","volume":"313","author":"H Okazawa","year":"1992","unstructured":"Okazawa H, Murata M, Watanabe M, Kamei M, Kanazawa I. Dopaminergic stimulation up-regulates the in vivo expression of brain-derived neurotrophic factor (BDNF) in the striatum. FEBS Lett. 1992;313(2):138\u201342.","journal-title":"FEBS Lett."},{"issue":"1","key":"160_CR58","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.brainres.2006.04.019","volume":"1095","author":"X Zhang","year":"2006","unstructured":"Zhang X, Andren PE, Svenningsson P. Repeated l-Dopa treatment increases c-fos and BDNF mRNAs in the subthalamic nucleus in the 6-OHDA rat model of Parkinson\u2019s disease. Brain Res. 2006;1095(1):207\u201310.","journal-title":"Brain Res."},{"issue":"1","key":"160_CR59","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/jnr.490370118","volume":"37","author":"MA Hynes","year":"1994","unstructured":"Hynes MA, Poulsen K, Armanini M, Berkemeier L, Phillips H, Rosenthal A. Neurotrophin-4\/5 is a survival factor for embryonic midbrain dopaminergic neurons in enriched cultures. J Neurosci Res. 1994;37(1):144\u201354.","journal-title":"J Neurosci Res."},{"issue":"1","key":"160_CR60","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1006\/exnr.2000.7339","volume":"163","author":"P Lingor","year":"2000","unstructured":"Lingor P, Unsicker K, Krieglstein K. GDNF and NT-4 protect midbrain dopaminergic neurons from toxic damage by iron and nitric oxide. Exp Neurol. 2000;163(1):55\u201362.","journal-title":"Exp Neurol."},{"issue":"1","key":"160_CR61","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0006-8993(95)01427-6","volume":"712","author":"NS Haque","year":"1996","unstructured":"Haque NS, Hlavin ML, Fawcett JW, Dunnett SB. The neurotrophin NT4\/5, but not NT3, enhances the efficacy of nigral grafts in a rat model of Parkinson\u2019s disease. Brain Res. 1996;712(1):45\u201352.","journal-title":"Brain Res."},{"issue":"1257","key":"160_CR62","first-page":"1","volume":"27","author":"S Gu","year":"2009","unstructured":"Gu S, Huang H, Bi J, Yao Y, Wen T. Combined treatment of neurotrophin-3 gene and neural stem cells is ameliorative to behavior recovery of Parkinson\u2019s disease rat model. Brain Res. 2009;27(1257):1\u20139.","journal-title":"Brain Res."},{"issue":"3","key":"160_CR63","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1046\/j.1471-4159.1994.63031021.x","volume":"63","author":"CA Altar","year":"1994","unstructured":"Altar CA, Boylan CB, Fritsche M, Jones BE, Jackson C, Wiegand SJ, et al. Efficacy of brain-derived neurotrophic factor and neurotrophin-3 on neurochemical and behavioral deficits associated with partial nigrostriatal dopamine lesions. J Neurochem. 1994;63(3):1021\u201332.","journal-title":"J Neurochem."},{"issue":"5111","key":"160_CR64","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1126\/science.8493557","volume":"260","author":"LF Lin","year":"1993","unstructured":"Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 1993;260(5111):1130\u20132.","journal-title":"Science."},{"issue":"6608","key":"160_CR65","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/384467a0","volume":"384","author":"PT Kotzbauer","year":"1996","unstructured":"Kotzbauer PT, Lampe PA, Heuckeroth RO, Golden JP, Creedon DJ, Johnson EM Jr, et al. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature. 1996;384(6608):467\u201370.","journal-title":"Nature."},{"issue":"6","key":"160_CR66","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0896-6273(00)80649-2","volume":"21","author":"RH Baloh","year":"1998","unstructured":"Baloh RH, Tansey MG, Lampe PA, Fahrner TJ, Enomoto H, Simburger KS, et al. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex. Neuron. 1998;21(6):1291\u2013302.","journal-title":"Neuron."},{"issue":"2","key":"160_CR67","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0896-6273(00)80453-5","volume":"20","author":"J Milbrandt","year":"1998","unstructured":"Milbrandt J, de Sauvage FJ, Fahrner TJ, Baloh RH, Leitner ML, Tansey MG, et al. Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron. 1998;20(2):245\u201353.","journal-title":"Neuron."},{"issue":"Pt 19","key":"160_CR68","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1242\/jcs.00786","volume":"116","author":"H Sariola","year":"2003","unstructured":"Sariola H, Saarma M. Novel functions and signalling pathways for GDNF. J Cell Sci. 2003;116(Pt 19):3855\u201362.","journal-title":"J Cell Sci."},{"issue":"3","key":"160_CR69","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0896-6273(02)01002-4","volume":"36","author":"F Ledda","year":"2002","unstructured":"Ledda F, Paratcha G, Ibanez CF. Target-derived GFRalpha1 as an attractive guidance signal for developing sensory and sympathetic axons via activation of Cdk5. Neuron. 2002;36(3):387\u2013401.","journal-title":"Neuron."},{"issue":"1","key":"160_CR70","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0896-6273(01)00188-X","volume":"29","author":"G Paratcha","year":"2001","unstructured":"Paratcha G, Ledda F, Baars L, Coulpier M, Besset V, Anders J, et al. Released GFRalpha1 potentiates downstream signaling, neuronal survival, and differentiation via a novel mechanism of recruitment of c-Ret to lipid rafts. Neuron. 2001;29(1):171\u201384.","journal-title":"Neuron."},{"issue":"7","key":"160_CR71","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0092-8674(03)00435-5","volume":"113","author":"G Paratcha","year":"2003","unstructured":"Paratcha G, Ledda F, Ibanez CF. The neural cell adhesion molecule NCAM is an alternative signaling receptor for GDNF family ligands. Cell. 2003;113(7):867\u201379.","journal-title":"Cell."},{"issue":"1","key":"160_CR72","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1046\/j.1471-4159.1999.0730070.x","volume":"73","author":"P Akerud","year":"1999","unstructured":"Akerud P, Alberch J, Eketjall S, Wagner J, Arenas E. Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons. J Neurochem. 1999;73(1):70\u20138.","journal-title":"J Neurochem."},{"issue":"1","key":"160_CR73","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1046\/j.1471-4159.1996.66010074.x","volume":"66","author":"JG Hou","year":"1996","unstructured":"Hou JG, Lin LF, Mytilineou C. Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium. J Neurochem. 1996;66(1):74\u201382.","journal-title":"J Neurochem."},{"issue":"7","key":"160_CR74","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nn.2136","volume":"11","author":"A Pascual","year":"2008","unstructured":"Pascual A, Hidalgo-Figueroa M, Piruat JI, Pintado CO, Gomez-Diaz R, Lopez-Barneo J. Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat Neurosci. 2008;11(7):755\u201361.","journal-title":"Nat Neurosci."},{"issue":"3","key":"160_CR75","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0304-3940(99)00443-7","volume":"269","author":"K Eggert","year":"1999","unstructured":"Eggert K, Schlegel J, Oertel W, Wurz C, Krieg JC, Vedder H. Glial cell line-derived neurotrophic factor protects dopaminergic neurons from 6-hydroxydopamine toxicity in vitro. Neurosci Lett. 1999;269(3):178\u201382.","journal-title":"Neurosci Lett."},{"issue":"6512","key":"160_CR76","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/373335a0","volume":"373","author":"A Tomac","year":"1995","unstructured":"Tomac A, Lindqvist E, Lin LF, Ogren SO, Young D, Hoffer BJ, et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature. 1995;373(6512):335\u20139.","journal-title":"Nature."},{"issue":"4","key":"160_CR77","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1523\/JNEUROSCI.4421-04.2005","volume":"25","author":"A Eslamboli","year":"2005","unstructured":"Eslamboli A, Georgievska B, Ridley RM, Baker HF, Muzyczka N, Burger C, et al. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson\u2019s disease. J Neurosci. 2005;25(4):769\u201377.","journal-title":"J Neurosci."},{"issue":"8","key":"160_CR78","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1080\/01616412.2000.11740761","volume":"22","author":"M Aoi","year":"2000","unstructured":"Aoi M, Date I, Tomita S, Ohmoto T. Single or continuous injection of glial cell line-derived neurotrophic factor in the striatum induces recovery of the nigrostriatal dopaminergic system. Neurol Res. 2000;22(8):832\u20136.","journal-title":"Neurol Res."},{"issue":"8","key":"160_CR79","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1046\/j.0953-816x.2001.01534.x","volume":"13","author":"D Kirik","year":"2001","unstructured":"Kirik D, Georgievska B, Rosenblad C, Bjorklund A. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson\u2019s disease. Eur J Neurosci. 2001;13(8):1589\u201399.","journal-title":"Eur J Neurosci."},{"key":"160_CR80","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1038\/srep02786","volume":"3","author":"Z Ren","year":"2013","unstructured":"Ren Z, Wang J, Wang S, Zou C, Li X, Guan Y, et al. Autologous transplantation of GDNF-expressing mesenchymal stem cells protects against MPTP-induced damage in cynomolgus monkeys. Sci Rep. 2013;3:2786.","journal-title":"Sci Rep."},{"issue":"13","key":"160_CR81","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1523\/JNEUROSCI.18-13-04929.1998","volume":"18","author":"BA Horger","year":"1998","unstructured":"Horger BA, Nishimura MC, Armanini MP, Wang LC, Poulsen KT, Rosenblad C, et al. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci. 1998;18(13):4929\u201337.","journal-title":"J Neurosci."},{"issue":"2","key":"160_CR82","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0006-8993(02)02934-7","volume":"947","author":"Y Oiwa","year":"2002","unstructured":"Oiwa Y, Yoshimura R, Nakai K, Itakura T. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson\u2019s disease. Brain Res. 2002;947(2):271\u201383.","journal-title":"Brain Res."},{"issue":"2","key":"160_CR83","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.parkreldis.2006.07.015","volume":"13","author":"WG Liu","year":"2007","unstructured":"Liu WG, Lu GQ, Li B, Chen SD. Dopaminergic neuroprotection by neurturin-expressing c17.2 neural stem cells in a rat model of Parkinson\u2019s disease. Parkinsonism Relat Disord. 2007;13(2):77\u201388.","journal-title":"Parkinsonism Relat Disord."},{"issue":"6","key":"160_CR84","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ana.21032","volume":"60","author":"JH Kordower","year":"2006","unstructured":"Kordower JH, Herzog CD, Dass B, Bakay RA, Stansell J 3rd, Gasmi M, et al. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol. 2006;60(6):706\u201315.","journal-title":"Ann Neurol."},{"issue":"4","key":"160_CR85","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3727\/096368908784423256","volume":"17","author":"R Grondin","year":"2008","unstructured":"Grondin R, Zhang Z, Ai Y, Ding F, Walton AA, Surgener SP, et al. Intraputamenal infusion of exogenous neurturin protein restores motor and dopaminergic function in the globus pallidus of MPTP-lesioned rhesus monkeys. Cell Transplant. 2008;17(4):373\u201381.","journal-title":"Cell Transplant."},{"issue":"2","key":"160_CR86","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1006\/mcne.1999.0817","volume":"15","author":"C Rosenblad","year":"2000","unstructured":"Rosenblad C, Gronborg M, Hansen C, Blom N, Meyer M, Johansen J, et al. In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin\/artemin. Mol Cell Neurosci. 2000;15(2):199\u2013214.","journal-title":"Mol Cell Neurosci."},{"issue":"1\u20132","key":"160_CR87","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.brainresbull.2004.10.012","volume":"68","author":"KB Zihlmann","year":"2005","unstructured":"Zihlmann KB, Ducray AD, Schaller B, Huber AW, Krebs SH, Andres RH, et al. The GDNF family members neurturin, artemin and persephin promote the morphological differentiation of cultured ventral mesencephalic dopaminergic neurons. Brain Res Bull. 2005;68(1\u20132):42\u201353.","journal-title":"Brain Res Bull."},{"issue":"2","key":"160_CR88","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1006\/mcne.2002.1171","volume":"21","author":"P Akerud","year":"2002","unstructured":"Akerud P, Holm PC, Castelo-Branco G, Sousa K, Rodriguez FJ, Arenas E. Persephin-overexpressing neural stem cells regulate the function of nigral dopaminergic neurons and prevent their degeneration in a model of Parkinson\u2019s disease. Mol Cell Neurosci. 2002;21(2):205\u201322.","journal-title":"Mol Cell Neurosci."},{"issue":"2","key":"160_CR89","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1385\/JMN:20:2:173","volume":"20","author":"P Petrova","year":"2003","unstructured":"Petrova P, Raibekas A, Pevsner J, Vigo N, Anafi M, Moore MK, et al. MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J Mol Neurosci. 2003;20(2):173\u201388.","journal-title":"J Mol Neurosci."},{"issue":"7149","key":"160_CR90","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nature05957","volume":"448","author":"P Lindholm","year":"2007","unstructured":"Lindholm P, Voutilainen MH, Lauren J, Peranen J, Leppanen VM, Andressoo JO, et al. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature. 2007;448(7149):73\u20137.","journal-title":"Nature."},{"issue":"3","key":"160_CR91","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.mcn.2008.07.016","volume":"39","author":"P Lindholm","year":"2008","unstructured":"Lindholm P, Peranen J, Andressoo JO, Kalkkinen N, Kokaia Z, Lindvall O, et al. MANF is widely expressed in mammalian tissues and differently regulated after ischemic and epileptic insults in rodent brain. Mol Cell Neurosci. 2008;39(3):356\u201371.","journal-title":"Mol Cell Neurosci."},{"issue":"6","key":"160_CR92","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3727\/096368911X600948","volume":"21","author":"M Airavaara","year":"2012","unstructured":"Airavaara M, Harvey BK, Voutilainen MH, Shen H, Chou J, Lindholm P, et al. CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice. Cell Transplant. 2012;21(6):1213\u201323.","journal-title":"Cell Transplant."},{"issue":"2","key":"160_CR93","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/brb3.117","volume":"3","author":"S Back","year":"2013","unstructured":"Back S, Peranen J, Galli E, Pulkkila P, Lonka-Nevalaita L, Tamminen T, et al. Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson\u2019s disease. Brain Behav. 2013;3(2):75\u201388.","journal-title":"Brain Behav."},{"issue":"1","key":"160_CR94","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.expneurol.2010.12.013","volume":"228","author":"MH Voutilainen","year":"2011","unstructured":"Voutilainen MH, Back S, Peranen J, Lindholm P, Raasmaja A, Mannisto PT, et al. Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson\u2019s disease. Exp Neurol. 2011;228(1):99\u2013108.","journal-title":"Exp Neurol."},{"issue":"30","key":"160_CR95","doi-asserted-by":"crossref","first-page":"9651","DOI":"10.1523\/JNEUROSCI.0833-09.2009","volume":"29","author":"MH Voutilainen","year":"2009","unstructured":"Voutilainen MH, Back S, Porsti E, Toppinen L, Lindgren L, Lindholm P, et al. Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson\u2019s disease. J Neurosci. 2009;29(30):9651\u20139.","journal-title":"J Neurosci."},{"issue":"4","key":"160_CR96","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1074\/jbc.M110.146738","volume":"286","author":"M Hellman","year":"2011","unstructured":"Hellman M, Arumae U, Yu LY, Lindholm P, Peranen J, Saarma M, et al. Mesencephalic astrocyte-derived neurotrophic factor (MANF) has a unique mechanism to rescue apoptotic neurons. J Biol Chem. 2011;286(4):2675\u201380.","journal-title":"J Biol Chem."},{"issue":"1","key":"160_CR97","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/exnr.2000.7483","volume":"166","author":"DW Howells","year":"2000","unstructured":"Howells DW, Porritt MJ, Wong JY, Batchelor PE, Kalnins R, Hughes AJ, et al. Reduced BDNF mRNA expression in the Parkinson\u2019s disease substantia nigra. Exp Neurol. 2000;166(1):127\u201335.","journal-title":"Exp Neurol."},{"issue":"3","key":"160_CR98","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/00001756-199902250-00021","volume":"10","author":"K Parain","year":"1999","unstructured":"Parain K, Murer MG, Yan Q, Faucheux B, Agid Y, Hirsch E, et al. Reduced expression of brain-derived neurotrophic factor protein in Parkinson\u2019s disease substantia nigra. Neuroreport. 1999;10(3):557\u201361.","journal-title":"Neuroreport."},{"issue":"7","key":"160_CR99","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00415-005-0756-5","volume":"252","author":"T Foltynie","year":"2005","unstructured":"Foltynie T, Lewis SG, Goldberg TE, Blackwell AD, Kolachana BS, Weinberger DR, et al. The BDNF Val66 Met polymorphism has a gender specific influence on planning ability in Parkinson\u2019s disease. J Neurol. 2005;252(7):833\u20138.","journal-title":"J Neurol."},{"issue":"2","key":"160_CR100","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/jnnp.2008.154294","volume":"80","author":"T Foltynie","year":"2009","unstructured":"Foltynie T, Cheeran B, Williams-Gray CH, Edwards MJ, Schneider SA, Weinberger D, et al. BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2009;80(2):141\u20134.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"4","key":"160_CR101","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.parkreldis.2003.12.003","volume":"10","author":"A Parsian","year":"2004","unstructured":"Parsian A, Sinha R, Racette B, Zhao JH, Perlmutter JS. Association of a variation in the promoter region of the brain-derived neurotrophic factor gene with familial Parkinson\u2019s disease. Parkinsonism Relat Disord. 2004;10(4):213\u20139.","journal-title":"Parkinsonism Relat Disord."},{"key":"160_CR102","doi-asserted-by":"crossref","unstructured":"Toda T, Momose Y, Murata M, Tamiya G, Yamamoto M, Hattori N, et al. Toward identification of susceptibility genes for sporadic Parkinson\u2019s disease. J Neurol. 2003;250 Suppl 3:III40\u20133.","DOI":"10.1007\/s00415-003-1307-6"},{"issue":"2","key":"160_CR103","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bbrc.2011.04.030","volume":"408","author":"L Chen","year":"2011","unstructured":"Chen L, Wang Y, Xiao H, Wang L, Wang C, Guo S, et al. The 712A\/G polymorphism of brain-derived neurotrophic factor is associated with Parkinson\u2019s disease but not major depressive disorder in a Chinese Han population. Biochem Biophys Res Commun. 2011;408(2):318\u201321.","journal-title":"Biochem Biophys Res Commun."},{"issue":"11","key":"160_CR104","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1212\/01.wnl.0000187075.81589.fd","volume":"65","author":"S Karamohamed","year":"2005","unstructured":"Karamohamed S, Latourelle JC, Racette BA, Perlmutter JS, Wooten GF, Lew M, et al. BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study. Neurology. 2005;65(11):1823\u20135.","journal-title":"Neurology."},{"issue":"1","key":"160_CR105","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ana.10079","volume":"51","author":"Y Momose","year":"2002","unstructured":"Momose Y, Murata M, Kobayashi K, Tachikawa M, Nakabayashi Y, Kanazawa I, et al. Association studies of multiple candidate genes for Parkinson\u2019s disease using single nucleotide polymorphisms. Ann Neurol. 2002;51(1):133\u20136.","journal-title":"Ann Neurol."},{"issue":"11","key":"160_CR106","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/j.1468-1331.2009.02706.x","volume":"16","author":"FR Guerini","year":"2009","unstructured":"Guerini FR, Beghi E, Riboldazzi G, Zangaglia R, Pianezzola C, Bono G, et al. BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson\u2019s disease. Eur J Neurol. 2009;16(11):1240\u20135.","journal-title":"Eur J Neurol."},{"issue":"2","key":"160_CR107","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.parkreldis.2011.09.002","volume":"18","author":"J Liu","year":"2012","unstructured":"Liu J, Zhou Y, Wang C, Wang T, Zheng Z, Chan P. Brain-derived neurotrophic factor (BDNF) genetic polymorphism greatly increases risk of leucine-rich repeat kinase 2 (LRRK2) for Parkinson\u2019s disease. Parkinsonism Relat Disord. 2012;18(2):140\u20133.","journal-title":"Parkinsonism Relat Disord."},{"issue":"3","key":"160_CR108","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2377-3-6","volume":"26","author":"K Wirdefeldt","year":"2003","unstructured":"Wirdefeldt K, Burgess CE, Westerberg L, Payami H, Schalling M. A linkage study of candidate loci in familial Parkinson\u2019s Disease. BMC Neurol. 2003;26(3):6.","journal-title":"BMC Neurol."},{"issue":"3","key":"160_CR109","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/ana.410360310","volume":"36","author":"T Gasser","year":"1994","unstructured":"Gasser T, Wszolek ZK, Trofatter J, Ozelius L, Uitti RJ, Lee CS, et al. Genetic linkage studies in autosomal dominant parkinsonism: evaluation of seven candidate genes. Ann Neurol. 1994;36(3):387\u201396.","journal-title":"Ann Neurol."},{"issue":"12","key":"160_CR110","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.jocn.2011.03.015","volume":"18","author":"C Karakasis","year":"2011","unstructured":"Karakasis C, Kalinderi K, Katsarou Z, Fidani L, Bostantjopoulou S. Association of brain-derived neurotrophic factor (BDNF) Val66Met polymorphism with Parkinson\u2019s disease in a Greek population. J Clin Neurosci. 2011;18(12):1744\u20135.","journal-title":"J Clin Neurosci."},{"issue":"1","key":"160_CR111","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ajmg.b.30109","volume":"134B","author":"QR Liu","year":"2005","unstructured":"Liu QR, Walther D, Drgon T, Polesskaya O, Lesnick TG, Strain KJ, et al. Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson\u2019s Disease. Am J Med Genet B Neuropsychiatr Genet. 2005;134B(1):93\u2013103.","journal-title":"Am J Med Genet B Neuropsychiatr Genet."},{"issue":"2","key":"160_CR112","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ana.10665","volume":"54","author":"T Masaki","year":"2003","unstructured":"Masaki T, Matsushita S, Arai H, Takeda A, Itoyama Y, Mochizuki H, et al. Association between a polymorphism of brain-derived neurotrophic factor gene and sporadic Parkinson\u2019s disease. Ann Neurol. 2003;54(2):276\u20137.","journal-title":"Ann Neurol."},{"issue":"8","key":"160_CR113","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/mds.20491","volume":"20","author":"M Nishimura","year":"2005","unstructured":"Nishimura M, Kuno S, Kaji R, Kawakami H. Brain-derived neurotrophic factor gene polymorphisms in Japanese patients with sporadic Alzheimer\u2019s disease, Parkinson\u2019s disease, and multiple system atrophy. Mov Disord. 2005;20(8):1031\u20133.","journal-title":"Mov Disord."},{"issue":"6","key":"160_CR114","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/ana.10585","volume":"53","author":"A Hakansson","year":"2003","unstructured":"Hakansson A, Melke J, Westberg L, Shahabi HN, Buervenich S, Carmine A, et al. Lack of association between the BDNF Val66Met polymorphism and Parkinson\u2019s disease in a Swedish population. Ann Neurol. 2003;53(6):823.","journal-title":"Ann Neurol."},{"issue":"1","key":"160_CR115","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neulet.2003.09.009","volume":"353","author":"CJ Hong","year":"2003","unstructured":"Hong CJ, Liu HC, Liu TY, Lin CH, Cheng CY, Tsai SJ. Brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms in Parkinson\u2019s disease and age of onset. Neurosci Lett. 2003;353(1):75\u20137.","journal-title":"Neurosci Lett."},{"issue":"1","key":"160_CR116","first-page":"12","volume":"44","author":"MS Saarela","year":"2006","unstructured":"Saarela MS, Lehtimaki T, Rinne JO, Huhtala H, Rontu R, Hervonen A, et al. No association between the brain-derived neurotrophic factor 196 G>A or 270 C>T polymorphisms and Alzheimer\u2019s or Parkinson\u2019s disease. Folia Neuropathol. 2006;44(1):12\u20136.","journal-title":"Folia Neuropathol."},{"issue":"4","key":"160_CR117","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/ajmg.b.30476","volume":"144B","author":"CM Chen","year":"2007","unstructured":"Chen CM, Chen IC, Chang KH, Chen YC, Lyu RK, Liu YT, et al. Nuclear receptor NR4A2 IVS6 +18insG and brain derived neurotrophic factor (BDNF) V66M polymorphisms and risk of Taiwanese Parkinson\u2019s disease. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(4):458\u201362.","journal-title":"Am J Med Genet B Neuropsychiatr Genet."},{"issue":"1","key":"160_CR118","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1600-0404.2009.01253.x","volume":"122","author":"L Gao","year":"2010","unstructured":"Gao L, Diaz-Corrales FJ, Carrillo F, Diaz-Martin J, Caceres-Redondo MT, Carballo M, et al. Brain-derived neurotrophic factor G196A polymorphism and clinical features in Parkinson\u2019s disease. Acta Neurol Scand. 2010;122(1):41\u20135.","journal-title":"Acta Neurol Scand."},{"issue":"1","key":"160_CR119","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.neulet.2006.12.038","volume":"415","author":"G Xiromerisiou","year":"2007","unstructured":"Xiromerisiou G, Hadjigeorgiou GM, Eerola J, Fernandez HH, Tsimourtou V, Mandel R, et al. BDNF tagging polymorphisms and haplotype analysis in sporadic Parkinson\u2019s disease in diverse ethnic groups. Neurosci Lett. 2007;415(1):59\u201363.","journal-title":"Neurosci Lett."},{"issue":"11","key":"160_CR120","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s10038-005-0295-z","volume":"50","author":"E Zintzaras","year":"2005","unstructured":"Zintzaras E, Hadjigeorgiou GM. The role of G196A polymorphism in the brain-derived neurotrophic factor gene in the cause of Parkinson\u2019s disease: a meta-analysis. J Hum Genet. 2005;50(11):560\u20136.","journal-title":"J Hum Genet."},{"issue":"2","key":"160_CR121","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1006\/exnr.1998.6857","volume":"152","author":"K Wartiovaara","year":"1998","unstructured":"Wartiovaara K, Hytonen M, Vuori M, Paulin L, Rinne J, Sariola H. Mutation analysis of the glial cell line-derived neurotrophic factor gene in Parkinson\u2019s disease. Exp Neurol. 1998;152(2):307\u20139.","journal-title":"Exp Neurol."},{"issue":"1","key":"160_CR122","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.neurobiolaging.2008.03.006","volume":"31","author":"CB Lucking","year":"2010","unstructured":"Lucking CB, Lichtner P, Kramer ER, Gieger C, Illig T, Dichgans M, et al. Polymorphisms in the receptor for GDNF (RET) are not associated with Parkinson\u2019s disease in Southern Germany. Neurobiol Aging. 2010;31(1):167\u20138.","journal-title":"Neurobiol Aging."},{"issue":"8\u20139","key":"160_CR123","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/BF01291789","volume":"103","author":"S Hunot","year":"1996","unstructured":"Hunot S, Bernard V, Faucheux B, Boissiere F, Leguern E, Brana C, et al. Glial cell line-derived neurotrophic factor (GDNF) gene expression in the human brain: a post mortem in situ hybridization study with special reference to Parkinson\u2019s disease. J Neural Transm. 1996;103(8\u20139):1043\u201352.","journal-title":"J Neural Transm."},{"issue":"3","key":"160_CR124","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00213-010-1829-4","volume":"210","author":"RP Souza","year":"2010","unstructured":"Souza RP, de Luca V, Remington G, Lieberman JA, Meltzer HY, Kennedy JL, et al. Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia. Psychopharmacology (Berl). 2010;210(3):347\u201354.","journal-title":"Psychopharmacology (Berl)."},{"issue":"14","key":"160_CR125","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1093\/hmg\/ddq181","volume":"19","author":"D Fusco","year":"2010","unstructured":"Fusco D, Vargiolu M, Vidone M, Mariani E, Pennisi LF, Bonora E, et al. The RET51\/FKBP52 complex and its involvement in Parkinson disease. Hum Mol Genet. 2010;19(14):2804\u201316.","journal-title":"Hum Mol Genet."},{"issue":"1","key":"160_CR126","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1212\/WNL.60.1.69","volume":"60","author":"JG Nutt","year":"2003","unstructured":"Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER Jr, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003;60(1):69\u201373.","journal-title":"Neurology."},{"issue":"7","key":"160_CR127","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.bbadis.2009.02.009","volume":"1792","author":"T Bjorklund","year":"2009","unstructured":"Bjorklund T, Kirik D. Scientific rationale for the development of gene therapy strategies for Parkinson\u2019s disease. Biochim Biophys Acta. 2009;1792(7):703\u201313.","journal-title":"Biochim Biophys Acta."},{"issue":"3","key":"160_CR128","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q","volume":"46","author":"JH Kordower","year":"1999","unstructured":"Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, Cochran EJ, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson\u2019s disease. Ann Neurol. 1999;46(3):419\u201324.","journal-title":"Ann Neurol."},{"issue":"14","key":"160_CR129","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJM198804073181402","volume":"318","author":"SJ Kish","year":"1988","unstructured":"Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson\u2019s disease. Pathophysiologic and clinical implications. N Engl J Med. 1988;318(14):876\u201380.","journal-title":"N Engl J Med."},{"issue":"7309","key":"160_CR130","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/466916a","volume":"466","author":"B Vastag","year":"2010","unstructured":"Vastag B. Biotechnology: crossing the barrier. Nature. 2010;466(7309):916\u20138.","journal-title":"Nature."},{"issue":"5","key":"160_CR131","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm850","volume":"9","author":"SS Gill","year":"2003","unstructured":"Gill SS, Patel NK, Hotton GR, O\u2019Sullivan K, McCarter R, Bunnage M, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 2003;9(5):589\u201395.","journal-title":"Nat Med."},{"issue":"7","key":"160_CR132","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm0705-703","volume":"11","author":"S Love","year":"2005","unstructured":"Love S, Plaha P, Patel NK, Hotton GR, Brooks DJ, Gill SS. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med. 2005;11(7):703\u20134.","journal-title":"Nat Med."},{"issue":"2","key":"160_CR133","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.20374","volume":"57","author":"NK Patel","year":"2005","unstructured":"Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, Gill SS. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol. 2005;57(2):298\u2013302.","journal-title":"Ann Neurol."},{"issue":"2","key":"160_CR134","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3171\/jns.2005.102.2.0216","volume":"102","author":"JT Slevin","year":"2005","unstructured":"Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg. 2005;102(2):216\u201322.","journal-title":"J Neurosurg."},{"issue":"4","key":"160_CR135","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3171\/jns.2007.106.4.614","volume":"106","author":"JT Slevin","year":"2007","unstructured":"Slevin JT, Gash DM, Smith CD, Gerhardt GA, Kryscio R, Chebrolu H, et al. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1\u00a0year of treatment and 1\u00a0year of withdrawal. J Neurosurg. 2007;106(4):614\u201320.","journal-title":"J Neurosurg."},{"issue":"3","key":"160_CR136","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ana.20737","volume":"59","author":"AE Lang","year":"2006","unstructured":"Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol. 2006;59(3):459\u201366.","journal-title":"Ann Neurol."},{"issue":"Suppl 3","key":"160_CR137","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1016\/S1353-8020(09)70810-7","volume":"15","author":"RA Barker","year":"2009","unstructured":"Barker RA. Parkinson\u2019s disease and growth factors\u2014are they the answer? Parkinsonism Relat Disord. 2009;15(Suppl 3):S181\u20134.","journal-title":"Parkinsonism Relat Disord."},{"issue":"2","key":"160_CR138","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jneumeth.2006.06.015","volume":"163","author":"M Hutchinson","year":"2007","unstructured":"Hutchinson M, Gurney S, Newson R. GDNF in Parkinson disease: an object lesson in the tyranny of type II. J Neurosci Methods. 2007;163(2):190\u20132.","journal-title":"J Neurosci Methods."},{"issue":"6","key":"160_CR139","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s10875-007-9117-8","volume":"27","author":"SM Tatarewicz","year":"2007","unstructured":"Tatarewicz SM, Wei X, Gupta S, Masterman D, Swanson SJ, Moxness MS. Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson\u2019s disease receiving r-metHuGDNF via continuous intraputaminal infusion. J Clin Immunol. 2007;27(6):620\u20137.","journal-title":"J Clin Immunol."},{"issue":"2","key":"160_CR140","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.20861","volume":"21","author":"TB Sherer","year":"2006","unstructured":"Sherer TB, Fiske BK, Svendsen CN, Lang AE, Langston JW. Crossroads in GDNF therapy for Parkinson\u2019s disease. Mov Disord. 2006;21(2):136\u201341.","journal-title":"Mov Disord."},{"issue":"2","key":"160_CR141","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.expneurol.2005.12.021","volume":"198","author":"H Chebrolu","year":"2006","unstructured":"Chebrolu H, Slevin JT, Gash DA, Gerhardt GA, Young B, Given CA, et al. MRI volumetric and intensity analysis of the cerebellum in Parkinson\u2019s disease patients infused with glial-derived neurotrophic factor (GDNF). Exp Neurol. 2006;198(2):450\u20136.","journal-title":"Exp Neurol."},{"key":"160_CR142","doi-asserted-by":"crossref","unstructured":"The hard way to a Bill of Rights. Lancet Neurol. 2005;4(12):787.","DOI":"10.1016\/S1474-4422(05)70228-3"},{"issue":"3","key":"160_CR143","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1474-4422(06)70359-3","volume":"5","author":"AE Lang","year":"2006","unstructured":"Lang AE, Langston JW, Stoessl AJ, Brodsky M, Brooks DJ, Dhawan V, et al. GDNF in treatment of Parkinson\u2019s disease: response to editorial. Lancet Neurol. 2006;5(3):200\u20132.","journal-title":"Lancet Neurol."},{"issue":"5","key":"160_CR144","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","volume":"7","author":"WJ Marks Jr","year":"2008","unstructured":"Marks WJ Jr, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson\u2019s disease: an open-label, phase I trial. Lancet Neurol. 2008;7(5):400\u20138.","journal-title":"Lancet Neurol."},{"issue":"12","key":"160_CR145","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","volume":"9","author":"WJ Marks Jr","year":"2010","unstructured":"Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, et al. Gene delivery of AAV2-neurturin for Parkinson\u2019s disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9(12):1164\u201372.","journal-title":"Lancet Neurol."},{"issue":"1","key":"160_CR146","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/mds.23442","volume":"26","author":"RT Bartus","year":"2011","unstructured":"Bartus RT, Herzog CD, Chu Y, Wilson A, Brown L, Siffert J, et al. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson\u2019s disease and nonhuman primate brains. Mov Disord. 2011;26(1):27\u201336.","journal-title":"Mov Disord."},{"issue":"18","key":"160_CR147","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1212\/WNL.0b013e3182904faa","volume":"80","author":"RT Bartus","year":"2013","unstructured":"Bartus RT, Baumann TL, Siffert J, Herzog CD, Alterman R, Boulis N, et al. Safety\/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology. 2013;80(18):1698\u2013701.","journal-title":"Neurology."},{"issue":"3","key":"160_CR148","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neulet.2011.02.013","volume":"493","author":"JM Choi","year":"2011","unstructured":"Choi JM, Hong JH, Chae MJ, Ngyuen PH, Kang HS, Ma HI, et al. Analysis of mutations and the association between polymorphisms in the cerebral dopamine neurotrophic factor (CDNF) gene and Parkinson disease. Neurosci Lett. 2011;493(3):97\u2013101.","journal-title":"Neurosci Lett."},{"issue":"3","key":"160_CR149","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.pneurobio.2008.09.006","volume":"86","author":"A Saavedra","year":"2008","unstructured":"Saavedra A, Baltazar G, Duarte EP. Driving GDNF expression: the green and the red traffic lights. Prog Neurobiol. 2008;86(3):186\u2013215.","journal-title":"Prog Neurobiol."},{"key":"160_CR150","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1196\/annals.1403.011","volume":"1122","author":"O Weinreb","year":"2007","unstructured":"Weinreb O, Amit T, Bar-Am O, Youdim MB. Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann N Y Acad Sci. 2007;1122:155\u201368.","journal-title":"Ann N Y Acad Sci."},{"issue":"6","key":"160_CR151","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1566-2772(01)00019-6","volume":"1","author":"S Przedborski","year":"2001","unstructured":"Przedborski S, Vila M. MPTP: a review of its mechanisms of neurotoxicity. Clin Neurosci Res. 2001;1(6):407\u201318.","journal-title":"Clin Neurosci Res"},{"key":"160_CR152","doi-asserted-by":"crossref","unstructured":"Parkinson-Study-Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61(4):561\u20136.","DOI":"10.1001\/archneur.61.4.561"},{"issue":"13","key":"160_CR153","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","volume":"361","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease. N Engl J Med. 2009;361(13):1268\u201378.","journal-title":"N Engl J Med."},{"issue":"5","key":"160_CR154","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1474-4422(11)70073-4","volume":"10","author":"O Rascol","year":"2011","unstructured":"Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, et al. A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011;10(5):415\u201323.","journal-title":"Lancet Neurol."},{"issue":"7","key":"160_CR155","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1096\/fj.07-095398","volume":"22","author":"NP Visanji","year":"2008","unstructured":"Visanji NP, Orsi A, Johnston TH, Howson PA, Dixon K, Callizot N, et al. PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson\u2019s disease. FASEB J. 2008;22(7):2488\u201397.","journal-title":"FASEB J."},{"key":"160_CR156","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-3-211-73574-9_11","volume":"72","author":"EC Hirsch","year":"2007","unstructured":"Hirsch EC. Animal models in neurodegenerative diseases. J Neural Transm Suppl. 2007;72:87\u201390.","journal-title":"J Neural Transm Suppl."},{"issue":"3","key":"160_CR157","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3727\/000000006783982025","volume":"15","author":"K Soderstrom","year":"2006","unstructured":"Soderstrom K, O\u2019Malley J, Steece-Collier K, Kordower JH. Neural repair strategies for Parkinson\u2019s disease: insights from primate models. Cell Transplant. 2006;15(3):251\u201365.","journal-title":"Cell Transplant"},{"key":"160_CR158","first-page":"600","volume":"60","author":"LS Forno","year":"1993","unstructured":"Forno LS, DeLanney LE, Irwin I, Langston JW. Similarities and differences between MPTP-induced parkinsonsim and Parkinson\u2019s disease. Neuropathologic considerations. Adv Neurol. 1993;60:600\u20138.","journal-title":"Adv Neurol."},{"key":"160_CR159","doi-asserted-by":"crossref","unstructured":"Speciale SG. MPTP: insights into parkinsonian neurodegeneration. Neurotoxicol Teratol. 2002;24(5):607\u201320.","DOI":"10.1016\/S0892-0362(02)00222-2"},{"issue":"1","key":"160_CR160","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/mds.25108","volume":"28","author":"E Bezard","year":"2013","unstructured":"Bezard E, Yue Z, Kirik D, Spillantini MG. Animal models of Parkinson\u2019s disease: limits and relevance to neuroprotection studies. Mov Disord. 2013;28(1):61\u201370.","journal-title":"Mov Disord."},{"issue":"4","key":"160_CR161","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","volume":"164","author":"S Duty","year":"2011","unstructured":"Duty S, Jenner P. Animal models of Parkinson\u2019s disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol. 2011;164(4):1357\u201391.","journal-title":"Br J Pharmacol."},{"issue":"5","key":"160_CR162","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.neuron.2010.04.034","volume":"66","author":"TM Dawson","year":"2010","unstructured":"Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson\u2019s disease. Neuron. 2010;66(5):646\u201361.","journal-title":"Neuron."},{"issue":"2","key":"160_CR163","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.expneurol.2009.07.002","volume":"219","author":"M Piltonen","year":"2009","unstructured":"Piltonen M, Bespalov MM, Ervasti D, Matilainen T, Sidorova YA, Rauvala H, et al. Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons. Exp Neurol. 2009;219(2):499\u2013506.","journal-title":"Exp Neurol."},{"issue":"2","key":"160_CR164","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ana.20549","volume":"58","author":"DM Gash","year":"2005","unstructured":"Gash DM, Zhang Z, Ai Y, Grondin R, Coffey R, Gerhardt GA. Trophic factor distribution predicts functional recovery in parkinsonian monkeys. Ann Neurol. 2005;58(2):224\u201333.","journal-title":"Ann Neurol."},{"issue":"8","key":"160_CR165","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1523\/JNEUROSCI.21-08-02889.2001","volume":"21","author":"D Kirik","year":"2001","unstructured":"Kirik D, Winkler C, Bjorklund A. Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration. J Neurosci. 2001;21(8):2889\u201396.","journal-title":"J Neurosci."},{"issue":"4","key":"160_CR166","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0168-0102(00)00097-3","volume":"36","author":"M Aoi","year":"2000","unstructured":"Aoi M, Date I, Tomita S, Ohmoto T. The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages. Neurosci Res. 2000;36(4):319\u201325.","journal-title":"Neurosci Res."},{"issue":"6","key":"160_CR167","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/mt.2011.11","volume":"19","author":"RM Richardson","year":"2011","unstructured":"Richardson RM, Kells AP, Rosenbluth KH, Salegio EA, Fiandaca MS, Larson PS, et al. Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson\u2019s disease. Mol Ther. 2011;19(6):1048\u201357.","journal-title":"Mol Ther."},{"issue":"4","key":"160_CR168","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.pneurobio.2008.05.001","volume":"85","author":"T Deierborg","year":"2008","unstructured":"Deierborg T, Soulet D, Roybon L, Hall V, Brundin P. Emerging restorative treatments for Parkinson\u2019s disease. Prog Neurobiol. 2008;85(4):407\u201332.","journal-title":"Prog Neurobiol."},{"issue":"1","key":"160_CR169","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3171\/jns.2005.102.1.0080","volume":"102","author":"T Yasuhara","year":"2005","unstructured":"Yasuhara T, Shingo T, Muraoka K, Kobayashi K, Takeuchi A, Yano A, et al. Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease. J Neurosurg. 2005;102(1):80\u20139.","journal-title":"J Neurosurg."},{"issue":"6","key":"160_CR170","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","volume":"39","author":"W Dauer","year":"2003","unstructured":"Dauer W, Przedborski S. Parkinson\u2019s disease: mechanisms and models. Neuron. 2003;39(6):889\u2013909.","journal-title":"Neuron."},{"issue":"4","key":"160_CR171","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1517\/14728222.12.4.437","volume":"12","author":"JR Evans","year":"2008","unstructured":"Evans JR, Barker RA. Neurotrophic factors as a therapeutic target for Parkinson\u2019s disease. Expert Opin Ther Targets. 2008;12(4):437\u201347.","journal-title":"Expert Opin Ther Targets."},{"issue":"4","key":"160_CR172","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1474-4422(06)70386-6","volume":"5","author":"RA Barker","year":"2006","unstructured":"Barker RA. Continuing trials of GDNF in Parkinson\u2019s disease. Lancet Neurol. 2006;5(4):285\u20136.","journal-title":"Lancet Neurol."},{"issue":"2","key":"160_CR173","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.nbd.2006.10.005","volume":"25","author":"A Schober","year":"2007","unstructured":"Schober A, Peterziel H, von Bartheld CS, Simon H, Krieglstein K, Unsicker K. GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action. Neurobiol Dis. 2007;25(2):378\u201391.","journal-title":"Neurobiol Dis."},{"issue":"6","key":"160_CR174","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1073\/pnas.061020198","volume":"98","author":"FS Lee","year":"2001","unstructured":"Lee FS, Chao MV. Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc Natl Acad Sci U\u00a0S\u00a0A. 2001;98(6):3555\u201360.","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"7","key":"160_CR175","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/hipo.20294","volume":"17","author":"MJ Diogenes","year":"2007","unstructured":"Diogenes MJ, Assaife-Lopes N, Pinto-Duarte A, Ribeiro JA, Sebastiao AM. Influence of age on BDNF modulation of hippocampal synaptic transmission: interplay with adenosine A2A receptors. Hippocampus. 2007;17(7):577\u201385.","journal-title":"Hippocampus."},{"issue":"9","key":"160_CR176","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/npp.2011.64","volume":"36","author":"MJ Diogenes","year":"2011","unstructured":"Diogenes MJ, Costenla AR, Lopes LV, Jeronimo-Santos A, Sousa VC, Fontinha BM, et al. Enhancement of LTP in aged rats is dependent on endogenous BDNF. Neuropsychopharmacology. 2011;36(9):1823\u201336.","journal-title":"Neuropsychopharmacology."},{"issue":"12","key":"160_CR177","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1523\/JNEUROSCI.4454-03.2004","volume":"24","author":"MJ Diogenes","year":"2004","unstructured":"Diogenes MJ, Fernandes CC, Sebastiao AM, Ribeiro JA. Activation of adenosine A2A receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in hippocampal slices. J Neurosci. 2004;24(12):2905\u201313.","journal-title":"J Neurosci."},{"issue":"6","key":"160_CR178","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.neuropharm.2008.01.011","volume":"54","author":"BM Fontinha","year":"2008","unstructured":"Fontinha BM, Diogenes MJ, Ribeiro JA, Sebastiao AM. Enhancement of long-term potentiation by brain-derived neurotrophic factor requires adenosine A2A receptor activation by endogenous adenosine. Neuropharmacology. 2008;54(6):924\u201333.","journal-title":"Neuropharmacology."},{"issue":"1","key":"160_CR179","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1471-4159.2007.05046.x","volume":"104","author":"MT Tebano","year":"2008","unstructured":"Tebano MT, Martire A, Potenza RL, Gro C, Pepponi R, Armida M, et al. Adenosine A(2A) receptors are required for normal BDNF levels and BDNF-induced potentiation of synaptic transmission in the mouse hippocampus. J Neurochem. 2008;104(1):279\u201386.","journal-title":"J Neurochem."},{"issue":"1","key":"160_CR180","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.brainres.2006.07.025","volume":"1113","author":"CA Gomes","year":"2006","unstructured":"Gomes CA, Vaz SH, Ribeiro JA, Sebastiao AM. Glial cell line-derived neurotrophic factor (GDNF) enhances dopamine release from striatal nerve endings in an adenosine A2A receptor-dependent manner. Brain Res. 2006;1113(1):129\u201336.","journal-title":"Brain Res."},{"issue":"1\u20132","key":"160_CR181","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neulet.2006.05.036","volume":"404","author":"PA Pousinha","year":"2006","unstructured":"Pousinha PA, Diogenes MJ, Ribeiro JA, Sebastiao AM. Triggering of BDNF facilitatory action on neuromuscular transmission by adenosine A2A receptors. Neurosci Lett. 2006;404(1\u20132):143\u20137.","journal-title":"Neurosci Lett."},{"key":"160_CR182","doi-asserted-by":"crossref","unstructured":"Assaife-Lopes N, Sousa VC, Pereira DB, Ribeiro JA, Sebastiao AM. Regulation of TrkB receptor translocation to lipid rafts by adenosine A receptors and its functional implications for BDNF-induced regulation of synaptic plasticity. Purinergic Signal. 2013. http:\/\/dx.doi.org\/10.1007\/s11302-013-9383-2","DOI":"10.1007\/s11302-013-9383-2"},{"issue":"79C","key":"160_CR183","first-page":"389","volume":"18","author":"TM Rodrigues","year":"2013","unstructured":"Rodrigues TM, Jeronimo-Santos A, Sebastiao AM, Diogenes MJ. Adenosine A Receptors as novel upstream regulators of BDNF-mediated attenuation of hippocampal Long-Term Depression (LTD). Neuropharmacology. 2013;18(79C):389\u201398.","journal-title":"Neuropharmacology."},{"issue":"4","key":"160_CR184","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/0306-4522(96)00343-0","volume":"75","author":"C Rosenblad","year":"1996","unstructured":"Rosenblad C, Martinez-Serrano A, Bjorklund A. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. Neuroscience. 1996;75(4):979\u201385.","journal-title":"Neuroscience."},{"issue":"15\u201317","key":"160_CR185","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1097\/00001756-199611040-00029","volume":"7","author":"SR Sinclair","year":"1996","unstructured":"Sinclair SR, Svendsen CN, Torres EM, Martin D, Fawcett JW, Dunnett SB. GDNF enhances dopaminergic cell survival and fibre outgrowth in embryonic nigral grafts. Neuroreport. 1996;7(15\u201317):2547\u201352.","journal-title":"Neuroreport."},{"issue":"5","key":"160_CR186","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3171\/jns.2000.92.5.0863","volume":"92","author":"I Mendez","year":"2000","unstructured":"Mendez I, Dagher A, Hong M, Hebb A, Gaudet P, Law A, et al. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson\u2019s disease. Report of two cases and technical considerations. J Neurosurg. 2000;92(5):863\u20139.","journal-title":"J Neurosurg."}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-014-0160-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-014-0160-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-014-0160-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T21:57:52Z","timestamp":1716587872000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-014-0160-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,9]]},"references-count":186,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["160"],"URL":"https:\/\/doi.org\/10.1007\/s40266-014-0160-x","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,9]]}}}